Analyzing MDxHealth (NASDAQ:MDXH) & Movano (NASDAQ:MOVE)

Movano (NASDAQ:MOVE) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Insider and Institutional Ownership

16.6% of Movano shares are owned by institutional investors. 10.4% of Movano shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Movano and MDxHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Movano	-3,409.60%	-647.91%	-225.03%
MDxHealth	-31.07%	-1,078.01%	-21.71%

Risk & Volatility

Movano has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Movano and MDxHealth, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Movano	1	0	0	0	1.00
MDxHealth	1	0	4	0	2.60

MDxHealth has a consensus price target of $7.75, suggesting a potential upside of 217.62%. Given MDxHealth’s stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than Movano.

Valuation and Earnings

This table compares Movano and MDxHealth”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Movano	$1.01 million	20.70	-$23.73 million	($10.83)	-1.69
MDxHealth	$107.88 million	1.12	-$33.52 million	($0.67)	-3.64

Movano has higher earnings, but lower revenue than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than Movano, indicating that it is currently the more affordable of the two stocks.

Summary

MDxHealth beats Movano on 8 of the 14 factors compared between the two stocks.

About Movano

Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. It develops System-on-a-Chip (SoC) for blood pressure or continuous glucose monitoring (CGM) systems. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.